(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-4,5,6,7a-tetrahydro-3aH-thieno[2,3-b]thiopyran-2-sulfonamide | 1421321-06-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻烷
• 英文名称: (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-4,5,6,7a-tetrahydro-3aH-thieno[2,3-b]thiopyran-2-sulfonamide
• CAS: 1421321-06-3
• 化学式: C₁₀H₁₈N₂O₄S₃
• 分子量: 326.462
• InChiKey: GKNQVLUQWYYZMY-XWDWJLIRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  148
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  、 (4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-4,5,6,7a-tetrahydro-3aH-thieno[2,3-b]thiopyran-2-sulfonamide 在 2,6-二甲基吡啶 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  A multivalent approach towards linked dual-pharmacology prostaglandin F receptor agonist/carbonic anhydrase-II inhibitors for the treatment of glaucoma

  摘要：

  Lowering of intra-ocular pressure is the primary pharmacologic approach for the treatment of glaucoma and a number of distinct mechanisms of action have been clinically validated. Targeting of multiple mechanisms in combination therapies has proven effective both clinically and commercially although potential improvements with regards to efficacy, tolerability and dosing frequency remain. Application of Theravance's multivalent approach to drug discovery towards linked dual-pharmacology prostaglandin F receptor (FP) agonist/carbonic anhydrase (CA)-II inhibitor compounds is described. Compound 29 exhibits weak potency (pEC(50) = 5.7, IA >1.0) as an FP agonist with high binding affinity (pK(i) = 8.1) to the CA-II enzyme, and has comparable corneal permeability to the CA-II inhibitor dorzolamide. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.12.058